Literature DB >> 16489715

European Union regulatory draft guidance on biogenerics containing recombinant human erythropoietin.

Vladimir Trkulja.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16489715      PMCID： PMC2080362     

Source DB:  PubMed          Journal:  Croat Med J        ISSN： 0353-9504            Impact factor:   1.351


× No keyword cloud information.
  4 in total

1.  Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study.

Authors:  Francesco Locatelli; Conrad A Baldamus; Giuseppe Villa; Alexandru Ganea; Angel L Martín de Francisco
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860

2.  Recombinant protein therapeutics--success rates, market trends and values to 2010.

Authors:  Alex K Pavlou; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2004-12       Impact factor: 54.908

3.  Control of rHuEPO biological activity: the role of carbohydrate.

Authors:  Steve Elliott; Joan Egrie; Jeff Browne; Tony Lorenzini; Leigh Busse; Norma Rogers; Ian Ponting
Journal:  Exp Hematol       Date:  2004-12       Impact factor: 3.084

Review 4.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.